Investment Thesis
NNVC is a pre-revenue pharmaceutical company with unsustainable cash burn of $5.6M annually against only $3.2M in cash, implying less than 7 months of runway. Negative operating income of $6.1M and negative returns on equity (-65.5%) and assets (-58.7%) indicate the company is destroying shareholder value with no offsetting revenue generation. Without near-term revenue inflection or additional capital, the company faces imminent financial distress.
Strengths
- Current ratio of 3.17x indicates adequate short-term liquidity position
- Debt-to-equity ratio of 0.52x is moderate and not overleveraged
- Low capital expenditures ($84.3K) suggest capital-efficient R&D model
Risks
- Zero revenue with negative operating cash flow of $5.6M creates unsustainable burn rate and ~7 month cash runway
- Cannot service debt obligations with operating losses; interest coverage is -121.7x
- Pre-revenue pharmaceutical business model carries execution risk with no visible commercialization path or revenue timeline
Key Metrics to Watch
- Cash balance trend and months of runway remaining
- Operating cash flow and quarterly burn rate acceleration/deceleration
- Regulatory milestones and clinical trial progress announcements
Financial Metrics
Revenue
0.0
Net Income
-6.0M
EPS (Diluted)
$-0.31
Free Cash Flow
-5.7M
Total Assets
10.2M
Cash
3.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-65.5%
ROA
-58.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.17x
Quick Ratio
3.17x
Debt/Equity
0.52x
Debt/Assets
10.8%
Interest Coverage
-121.67x
Long-term Debt
4.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:53:29.660349 |
Data as of: 2026-03-31 |
Powered by Claude AI